

**EXHIBIT A**  
**PENDING CLAIMS**  
**AS OF FEBRUARY 21, 2003**  
**IN U.S. APPLICATION SERIAL NO.: 09/610,118**  
**ATTORNEY DOCKET NO.: 7853-211**

132. A substantially purified antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, wherein said antibody immunospecifically binds to a human TANGO 268 antigen.

133. The antibody of claim 132, wherein the antibody comprises a variable heavy (VH) CDR having an amino acid sequence of a VH CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

134. The antibody of claim 132, wherein the antibody comprises a variable light (VL) CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

135. The antibody of claim 133, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

136. The antibody of claim 134 or 135, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

138. The antibody of claim 133, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

140. The antibody of claim 138, further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

142. The antibody of claim 133, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

144. The antibody of claim 142, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

146. The antibody of claim 133, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

148. The antibody of claim 146, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

150. The antibody of claim 134, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

152. The antibody of claim 150, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

154. The antibody of claim 150, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

155. The antibody of claim 154, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

157. The antibody of claim 134, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

159. The antibody of claim 157, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

161. The antibody of claim 138 further comprising a VH CDR2 domain having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

162. The antibody of claim 138 further comprising a VH CDR3 domain having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

163. The antibody of claim 138 further comprising:

- (a) a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

164. The antibody of claim 138 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

165. The antibody of claim 138 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

168. The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

169. The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

171. The antibody of claim 138 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and

(b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

173. The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

175. The antibody of claim 142 further comprising a VH CDR3 having the amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

176. The antibody of claim 142 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

177. The antibody of claim 142 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

178. The antibody of claim 142 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

180. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

181. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

183. The antibody of claim 142 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

185. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

187. The antibody of claim 146 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

188. The antibody of claim 146 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

189. The antibody of claim 146 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

191. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

192. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

194. The antibody of claim 146 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

196. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

198. The antibody of claim 161, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

199. The antibody of claim 198, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

200. The antibody of claim 198, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

201. The antibody of claim 198, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

203. The antibody of claim 199 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

205. The antibody of claim 200 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

207. The antibody of claim 199, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

208. The antibody of claim 207, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

210. The antibody of claim 162, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

211. The antibody of claim 210, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

212. The antibody of claim 210, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

213. The antibody of claim 210, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

215. The antibody of claim 211, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

216. The antibody of claim 212, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

218. The antibody of claim 211 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

220. The antibody of claim 218 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

222. The antibody of claim 163 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

223. The antibody of claim 163 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

224. The antibody of claim 163 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

226. The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

227. The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

229. The antibody of claim 163 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

231. The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

233. The antibody of claim 175 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

234. The antibody of claim 175 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

235. The antibody of claim 175 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

237. The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

238. The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

240. The antibody of claim 175 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

242. The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

245. The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

246. The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

247. The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

248. The antibody of claim 245 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

249. The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

250. The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

251. The antibody of claim 248 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

252. A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

254. A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442 for binding to a human TANGO 268 antigen.

256. The antibody of claim 132, 133 or 134, wherein the antibody is a monoclonal antibody.

257. The antibody of claim 132, 133 or 134, wherein the antibody is a human antibody.

258. The antibody of claim 132, 133 or 134, wherein the antibody is a humanized antibody.

259. The antibody of claim 132, 133 or 134, wherein the antibody is a Fab fragment.

260. The antibody of claim 132, 133 or 134, wherein the antibody is an scFv.

261. The antibody of claim 132, 133 or 134, wherein the antibody is conjugated to a therapeutic or drug moiety.

262. The antibody of claim 132, 133 or 134, wherein the antibody is conjugated to a detectable substance.

263. A pharmaceutical composition comprising the antibody of claim 132, 133 or 134 and a pharmaceutically acceptable carrier.

264. A kit comprising the antibody of claim 132, 133 or 134 and instructions for use, in one or more containers.